Plasticell and LambdaGen team on off-the-shelf stem cell platform
The strategic partnership between UK-based Plasticell and Singapore-based LambdaGen will develop induced pluripotent stem cell (iPSCs) derived chimeric antigen receptor-natural killer (CAR-NK) allogenic cancer immunotherapies.
The collaboration is funded by EUREKA GlobalStars, an international research and development funding program.
The $650,000 partnership hopes to reduce manufacturing cost and increase immunoactivity for iPSC-derived allogenic cancer immunotherapies.
LambdaGen will be responsible for generating the iPSC lines engineered with CARs that enhance the anti-tumor activity of the body’s immune cells. Plasticell will use its combinatorial screening technology, CombiCult, to convert the iPSCs into NK cells.
There is a need for alternative ‘off-the-shelf’ immunotherapy products, which can be met by engineered NK cells capable of functioning in an allogeneic setting,” says Dr Marina Tarunina, research director of Plasticell.
ارسال به دوستان